$105 million was received in Series B investment by Attovia Therapeutics, a biotherapeutics pipeline developer located in Fremont, CA, with an initial emphasis on immune-mediated disorders.
Investors
- Goldman Sachs Alternatives
- Marshall Wace
- EcoR1 Capital
- Redmile Group
- Cormorant Asset Management
- Illumina Ventures
- Frazier Life Sciences
- venBio
- Logos Capital
Simultaneously with the funding, Goldman Sachs Alternatives’ Managing Director of Life Sciences Investing, Colin Walsh, Ph.D., was added to the board of directors.
Use of funds
The business plans to use the money to extend its pipeline for immunology and inflammation, push its main projects ATTO-1310 and ATTO-002 through early clinical data readouts, and enhance the ATTOBODYTM platform.
“We are grateful for the support from such a strong group of investors, which allows us to further expand our pipeline in novel bi-specifics, advance our lead programs to the clinic in the near term, and catalyze potential business development opportunities.”
Tao Fu
About Attovia Therapeutics
Attovia is developing a pipeline of biotherapeutics, first concentrating on immune-mediated disorders, under the direction of CEO Tao Fu. Compared to conventional methods, the company’s binders offer greater effectiveness and a wider range of druggable epitopes thanks to its biparatopic biologics platform, ATTOBODYTM. The lead initiatives, ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY, and ATTO-1310, a possible first-in-class, extended half-life anti-IL31 ATTOBODY, represent potential best-in-class therapies for a variety of immune-mediated disorders.
With IND enabling investigations underway, ATTO-1310 is expected to begin clinical trials by the end of 2024 to treat atopic dermatitis and other pruritic disorders. In the second half of 2024, Attovia plans to propose a development candidate for ATTO-002, and in 2025, the candidate will be advanced to IND.
The business is also working on discovery stage initiatives that will provide more multi-specific combinations and broaden the ATTOBODY platform’s reach to include new, challenging-to-treat targets.
